Inhibitors of V-type ATPases, bafilomycin A1 and concanamycin A, protect against β-amyloid-mediated effects on 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) reduction

Journal of Neurochemistry

Volumn 72, Issue 5, 1999, Pages 1939-1947

  Kane, Michael D ^a   Schwarz, Roy D ^a   St Pierre, Linda ^a   Watson, M Desiree ^a   Emmerling, Mark R ^a   Boxer, Peter A ^a   Walker, Glenn K ^b  

^a PFIZER INC   (United States)

^b EASTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Amyloid peptide; Bafilomycin; Concanamycin; PC12; Vacuolar type ATPase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE TRIPHOSPHATASE; AMYLOID BETA PROTEIN; BAFILOMYCIN A1; CONCANAMYCIN A; FORMAZAN; MACROLIDE; NERVE GROWTH FACTOR;

ACIDIFICATION; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENDOSOME; LYSOSOME; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATASES; AMYLOID BETA-PROTEIN; ANIMALS; ANTI-BACTERIAL AGENTS; COLORING AGENTS; ENZYME INHIBITORS; MACROLIDES; OXIDATION-REDUCTION; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; TETRAZOLIUM SALTS; THIAZOLES;

ANIMALIA;

EID: 0033005082     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0721939.x     Document Type: Article

References (47)

1. Barrow C. J. and Zagorski M. G. (1991) Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 253, 179-182.
2. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., and Poirier J. (1998) β-Amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J. Neurochem. 70, 1458-1466.
3. Behl C., Davis J., Cole G. M., and Schubert D. (1992) Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem. Biophys. Res. Commun. 186, 944-950.
4. Behl C., Davis J. B., Lesley R., and Schubert D. (1994) Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77, 817-827.
5. Bowman E. J., Siebers A., and Altendorf K. (1988) Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc. Natl. Acad. Sci. USA 85, 7972-7976.
6. Burdick D., Kosmoski J., Knauer M. F., and Glabe C. G. (1997) Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer's amyloid peptide, Aβ1-42, in differentiated PC12 cells. Brain Res. 746, 275-284.
7. Burgevin M.-C., Passat M., Daniel N., Capet M., and Doble A. (1994) Congo red protects against toxicity of β-amyloid peptides on rat hippocampal neurones. Neuroreport 5, 2429-2432.
8. Cooper G. J., Willis A. C., Clark A., Turner R. C., Sim R. B., and Reid K. B. (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. USA 84, 8628-8632.
9. Drose S. and Altendorf K. (1997) Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J. Exp. Biol. 200, 1-8.
10. Drose S., Bindseil K. U., Bowman E. J., Siebers A., Zeeck A., and Altendorf K. (1993) Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosine triphosphatases. Biochemistry 32, 3902-3906.
11. Giulian D., Haverkamp L. J., Yu J. H., Karshin W., Tom D., Li J., Kirkpatrick J., Kuo L. M., and Roher A. E. (1996) Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J. Neurosci. 16, 6021-6037.
12. Greene L. A. and Tischler A. S. (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA 73, 2424-2428.
13. Guinea R. and Carrasco L. (1995) Requirement for vacuolar proton-ATPase activity during entry of influenza virus in cells. J. Virol. 69, 2306-2312.
14. +-ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type beta-amyloid precursor protein. J. Biol. Chem. 270, 6186-6192.
15. Hansen M. B., Nielsen S. E., and Berg K. (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119, 203-210.
16. Heinle S., Stunkel K., Zahner H., Drautz H., and Bessler W. G. (1988) Immunosuppressive effects of the macrolide antibiotic bafilomycin towards lymphocytes and lymphoid cell lines. Arzneimittelforschung 38, 1130-1133.
17. + activated ATPase inhibitor, L-681,110 from the fermentation broth of Streptomyces sp. MA-5038. J. Antibiot. 37, 970-975.
18. Joseph J. A., Strain J. G., Jimenez N. D., and Fisher D. (1997) Oxidant injury in PC12 cells - a possible model of calcium "dysregulation" in aging: I. Selectivity of protection against oxidative stress. J. Neurochem. 69, 1252-1258.
19. Kim K. S., Wen G. Y., Bancher C., Chen C. M. J., Sapienza V. J., Hong H., and Wisniewski H. M. (1990) Detection and quantitation of amyloid β-peptide with monoclonal antibodies. Neurosci. Res. Commun. 7, 113-130.
20. Kinashi H., Someno K., and Sakaguchi K. (1984) Isolation and characterization of concanamycins A, B and C. J. Antibiot. (Tokyo) 37, 1333-1343.
21. Knauer M. F., Soreghan B., Burdick D., Kosmoski J., and Glabe C. G. (1992) Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/β protein. Proc. Natl. Acad. Sci. USA 89, 7437-7441.
22. Knops J., Suomensaari S., Lee M., McConlogue L., Seubert P., and Sinha S. (1995) Cell-type and amyloid precursor protein-type specific inhibition of Aβ release by bafilomycin A1, a selective inhibitor of vacuolar ATPases. J. Biol. Chem. 270, 2419-2422.
23. Liu Y. and Schubert D. (1997) Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J. Neurochem. 69, 2285-2293.
24. Liu Y., Peterson D., Kimura H., and Schubert D. (1997) The mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 69, 581-593.
25. MacGibbon G. A., Cooper G. J., and Dragunow M. (1997) Acute application of human amylin, unlike beta-amyloid peptides, kills undifferentiated PC12 cells by apoplosis. Neuroreport 8, 3945-3950.
26. Mattson M. P. (1997) Central role of oxyradicals in the mechanism of amyloid β-peptide cytotoxicity. Alzheimers Dis. Rev. 2, 1-14.
27. Mehta P. D., Dalton A. J., Mehta S. P., Kim K. S., Sersen E. A., and Wisniewski H. M. (1998) Increased plasma amyloid β protein 1-42 levels in Down syndrome. Neurosci. Lett. 241, 13-16.
28. Mellman I. (1987) Molecular sorting during endocytosis. Kidney Int. [Suppl.] 23, S184-S200.
29. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. J. Immunol. Methods 65, 55-63.
30. Naiki H. and Nakakuki K. (1996) First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab. Invest. 74, 374-383.
31. Paresce D. M., Ghosh R. N., and Maxfield F. R. (1996) Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17, 553-565.
32. +-ATPase in animal virus entry. J. Gen. Virol. 75, 2595-2606.
33. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
34. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G., and Cotman C. W. (1995) Structure-activity analyses of β-amyloid peptides: contributions of the 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253-265.
35. Pike C. J., Ramezan-Arab N., and Cotman C. W. (1997) β-Amyloid neurotoxicity in vitro: evidence of oxidative stress but not protection by antioxidants. J. Neurochem. 69, 1601-1611.
36. Podlisny M. B., Walsh D. M., Amarante P., Ostaszewski B. L., Stimson E. R., Maggio J. E., Teplow D. B., and Selkoe D. J. (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37, 3602-3611.
37. Rogers J., Webster S., Lue L. F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., and McGeer P. (1996) Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging 17, 681-686.
38. Schrader-Fischer G. and Paganetti P. A. (1996) Effect of alkalizing agents on the processing of the β-amyloid precursor protein. Brain Res. 716, 91-100.
39. Schwarz R. D., Kane M. D., Emmerling M. W., St. Pierre L., and Watson M. D. (1998) Aβ(1-42) is taken up into NGF-differentiated PC12 cells in a fucoidan-sensitive manner. (Abstr.) Neurobiol. Aging 19, 537.
40. Shearman M. S., Hawtin S. R., and Tailor V. J. (1995) The intracellular component of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides. J. Neurochem. 65, 218-227.
41. +-ATPase. J. Biol. Chem. 265, 21940-21945.
42. Urmoneit B., Prikulis I., Wihl G., D'Urso D., Frank R., Heeren J., Beisiegel U., and Prior R. (1997) Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab. Invest. 77, 157-166.
43. Werner G., Hagenmaier H., Drautz H., Baumgartner A., and Zahner H. (1984) Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity. J. Antibiot. (Tokyo) 37, 110-117.
44. Wisniewski T., Ghiso J., and Frangione B. (1997) Biology of Aβ amyloid in Alzheimer's disease. Neurobiol. Dis. 4, 313-328.
45. Yan S. D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., and Schmidt A. M. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
46. Yan S. D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F., Collison K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S., Roher A., and Stern D. (1997) An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature 389, 689-695.
47. Yang A. J., Chandswangbhuvana D., Margol L., and Glabe C. G. (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1-42 pathogenesis. J. Neurosci. Res. 52, 691-698.